Boundless Bio reports Q1 EPS (60c), consensus (56c)

“We are encouraged by the progress of the KOMODO-1 trial,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio (BOLD). “We continue to expand the body of evidence supporting BBI-940’s kinesin degradation mechanism, with our recent AACR poster demonstrating anti-tumor activity and tumor regression across multiple ecDNA+ cancer models. These findings further strengthen our confidence in the therapeutic potential of BBI-940 as we advance the program through a first-in-human clinical trial.”